Fosun's Open Innovation Journey: From CIIE Exhibits to Medical Breakthroughs

Eight Years of Innovation at CIIE

• 💡 Fosun's consistent participation at the China International Import Expo (CIIE) for eight consecutive years highlights its commitment to global innovation.
• 🚀 The company has successfully transformed cutting-edge global technologies like the Da Vinci surgical system and robotic bronchoscopy into localized innovative products in China.
• ✅ Fosun showcased various innovations at CIIE, including the Marie upright particle therapy system and CAR-T cell therapy, introducing them to a wider audience.

Localized Medical Breakthroughs

• 🎯 The first locally innovated, China-developed Da Vinci Xi surgical system was launched in October 2023, with over 480 systems installed by September 2025, serving over 810,000 patients.
• 🧠 Intuitive Fosun's headquarters functions as the largest integrated R&D, production, and training base for Intuitive Surgical in the Asia-Pacific region, providing training to more than 15,000 medical professionals.
• 🌱 Fosun achieved a breakthrough in China's cell therapy field with Yi Kai Da (ejilunsai injection), marking it as the first CAR-T cell therapy product in the country.

Pioneering Innovative Drugs

• 🔬 Fosun has developed multiple "world's first" innovative drugs, such as HANSIZHUANG, HLX43, and HLX22, showcasing its strength in original innovation.
• 💊 HANSIZHUANG, the world's first anti-PD-1 monoclonal antibody for first-line small cell lung cancer, has received global regulatory approvals and orphan drug designation.
• 🔥 HANSIZHUANG also pioneered a perioperative treatment regimen for gastric cancer, potentially leading to a "chemotherapy-free era" by replacing postoperative adjuvant chemotherapy.
• ✨ HLX43 is an innovative PDL1 targeting ADC with strong potential as a broad-spectrum anti-cancer drug, offering dual benefits and reduced side effects.
• 🌟 HLX22 is the world's first anti-H2 targeted therapy for gastric cancer to receive Orphan Drug Designation (ODD) from both the EU and US, with global Phase 3 trials underway.

Open Innovation Strategy

• 🔑 Fosun's core globalization strategy emphasizes innovation capability and value chain integration, combining a global vision with deep local development.
• 🤝 The company embraces an open and collaborative approach, partnering with scientists and leading innovation-driven companies worldwide to build an open innovation platform.
• 🌐 Fosun's open innovation system aims to integrate with academia, capital markets, enterprises, and policies to foster original innovation through global cooperation and support high-quality healthcare development in China.